Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) made a significant announcement regarding its entry into an Agreement and Plan ...

Marinus regains ganaxolone’s commercial rights in Europe where the compound is approved for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) ...

NEXI-001 is under clinical development by NexImmune and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase ...

Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Pancreatic Cancer.

Immedica Pharma AB to acquire Marinus Pharmaceuticals in a tender offer and merger, strengthening its global rare disease business.

ORION CORPORATION PRESS RELEASE 30 DECEMBER 2024 at 14.00 EET Orion and Marinus terminate agreement for ganaxolone in Europe Orion Corporation ("Orion") and Marinus Pharmaceuticals, Inc.

Cyclins regulate steroid receptor action in cyclin-dependent kinase (CDK)-dependent and independent manners. In addition to regulating the cell cycle, cyclin A2 (CCNA2) also mediates female sex ...

Addition of the CDK 4/6 inhibitor improved progression-free survival by 15.2 months for patients with HR+/HER2+ advanced ...

Poster presentation details are below: Author: Molina et al Title: CID-078, a first-in-class oral cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft ...